These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 24715845)

  • 1. Side effects of standard adjuvant and neoadjuvant chemotherapy regimens according to age groups in primary breast cancer.
    Reinisch M; von Minckwitz G; Harbeck N; Janni W; Kümmel S; Kaufmann M; Elling D; Nekljudova V; Loibl S
    Breast Care (Basel); 2013 Mar; 8(1):60-6. PubMed ID: 24715845
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Primary prophylactic colony-stimulating factors for the prevention of chemotherapy-induced febrile neutropenia in breast cancer patients.
    Renner P; Milazzo S; Liu JP; Zwahlen M; Birkmann J; Horneber M
    Cochrane Database Syst Rev; 2012 Oct; 10():CD007913. PubMed ID: 23076939
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Toxicity and health-related quality of life in breast cancer patients receiving adjuvant docetaxel, doxorubicin, cyclophosphamide (TAC) or 5-fluorouracil, doxorubicin and cyclophosphamide (FAC): impact of adding primary prophylactic granulocyte-colony stimulating factor to the TAC regimen.
    Martín M; Lluch A; Seguí MA; Ruiz A; Ramos M; Adrover E; Rodríguez-Lescure A; Grosse R; Calvo L; Fernandez-Chacón C; Roset M; Antón A; Isla D; del Prado PM; Iglesias L; Zaluski J; Arcusa A; López-Vega JM; Muñoz M; Mel JR
    Ann Oncol; 2006 Aug; 17(8):1205-12. PubMed ID: 16766587
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical feasibility of (neo)adjuvant taxane-based chemotherapy in older patients: analysis of >4,500 patients from four German randomized breast cancer trials.
    Loibl S; von Minckwitz G; Harbeck N; Janni W; Elling D; Kaufmann M; Eggemann H; Nekljudova V; Sommer H; Kiechle M; Kümmel S
    Breast Cancer Res; 2008; 10(5):R77. PubMed ID: 18796139
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effectiveness of biosimilar filgrastim vs. original granulocyte colony-stimulating factors in febrile neutropenia prevention in breast cancer patients.
    Puértolas I; Frutos Pérez-Surio A; Alcácera MA; Andrés R; Salvador MDT
    Eur J Clin Pharmacol; 2018 Mar; 74(3):315-321. PubMed ID: 29152672
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase I/II trial of adjuvant dose-dense docetaxel/epirubicin/cyclophosphamide (TEC) in stage II and III breast cancer.
    Burdette-Radoux S; Wood ME; Olin JJ; Laughlin RS; Crocker AM; Ashikaga T; Muss HB
    Breast J; 2007; 13(3):274-80. PubMed ID: 17461902
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Febrile neutropenia in adjuvant and neoadjuvant chemotherapy for breast cancer: a retrospective study in routine clinical practice from a single institution.
    Bacrie J; Laurans M; Iorio P; Fourme E; Volters AB; Bozec L; Lerebours F; Dubot C; Bensaoula O; Benzidane B; Pierga JY; Lefeuvre D
    Support Care Cancer; 2018 Dec; 26(12):4097-4103. PubMed ID: 29855772
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oblimersen combined with docetaxel, adriamycin and cyclophosphamide as neo-adjuvant systemic treatment in primary breast cancer: final results of a multicentric phase I study.
    Rom J; von Minckwitz G; Eiermann W; Sievert M; Schlehe B; Marmé F; Schuetz F; Scharf A; Eichbaum M; Sinn HP; Kaufmann M; Sohn C; Schneeweiss A
    Ann Oncol; 2008 Oct; 19(10):1698-705. PubMed ID: 18477581
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PREPARE trial: a randomized phase III trial comparing preoperative, dose-dense, dose-intensified chemotherapy with epirubicin, paclitaxel and CMF versus a standard-dosed epirubicin/cyclophosphamide followed by paclitaxel ± darbepoetin alfa in primary breast cancer--results at the time of surgery.
    Untch M; Fasching PA; Konecny GE; von Koch F; Conrad U; Fett W; Kurzeder C; Lück HJ; Stickeler E; Urbaczyk H; Liedtke B; Salat C; Harbeck N; Müller V; Schmidt M; Hasmüller S; Lenhard M; Schuster T; Nekljudova V; Lebeau A; Loibl S; von Minckwitz G;
    Ann Oncol; 2011 Sep; 22(9):1988-1998. PubMed ID: 21385882
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term outcomes after adjuvant treatment of sequential versus combination docetaxel with doxorubicin and cyclophosphamide in node-positive breast cancer: BCIRG-005 randomized trial.
    Mackey JR; Pieńkowski T; Crown J; Sadeghi S; Martin M; Chan A; Saleh M; Sehdev S; Provencher L; Semiglazov V; Press MF; Sauter G; Lindsay M; Houé V; Buyse M; Drevot P; Hitier S; Bensfia S; Eiermann W
    Ann Oncol; 2016 Jun; 27(6):1041-1047. PubMed ID: 26940688
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prophylactic administration of granulocyte colony-stimulating factor in epirubicin and cyclophosphamide chemotherapy for Japanese breast cancer patients: a retrospective study.
    Sakurada T; Bando S; Zamami Y; Takechi K; Chuma M; Goda M; Kirino Y; Nakamura T; Teraoka K; Morimoto M; Tangoku A; Ishizawa K
    Cancer Chemother Pharmacol; 2019 Nov; 84(5):1107-1114. PubMed ID: 31502114
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Economic evaluation of intensive chemotherapy with prophylactic granulocyte colony-stimulating factor for patients with high-risk early breast cancer in Japan.
    Ishiguro H; Kondo M; Hoshi SL; Takada M; Nakamura S; Teramukai S; Yanagihara K; Toi M
    Clin Ther; 2010 Feb; 32(2):311-26. PubMed ID: 20206789
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Comparative study of chemosensitivity and efficacy between pirarubicin and epirubicin in breast cancer].
    Zang MF; Zhang YM; Zhi YH; Zhai Z; Zhang M; Gu F; Zhi XC
    Zhonghua Yi Xue Za Zhi; 2011 May; 91(20):1388-92. PubMed ID: 21756809
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Feasibility and safety of dose-dense docetaxel after conventional epirubicin and cyclophosphamide as adjuvant treatment for early breast cancer patients.
    Sanna G; Pestrin M; Zafarana E; Biagioni C; Cavaciocchi D; Turner N; Di Leo A; Biganzoli L
    Breast; 2013 Oct; 22(5):926-32. PubMed ID: 23707082
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pegfilgrastim +/- ciprofloxacin for primary prophylaxis with TAC (docetaxel/doxorubicin/cyclophosphamide) chemotherapy for breast cancer. Results from the GEPARTRIO study.
    von Minckwitz G; Kümmel S; du Bois A; Eiermann W; Eidtmann H; Gerber B; Hilfrich J; Huober J; Costa SD; Jackisch C; Grasshoff ST; Vescia S; Skacel T; Loibl S; Mehta KM; Kaufmann M;
    Ann Oncol; 2008 Feb; 19(2):292-8. PubMed ID: 17846019
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dose-dense FEC followed by dose-dense ixabepilone as neoadjuvant treatment for breast cancer patients: a feasibility study.
    Clavarezza M; Bordonaro R; Daniele B; Ferrandina G; Barni S; Turazza M; Coati F; De Matteis A; De Placido S; Cognetti F; Olmeo NA; Carrozza F; Bruzzi P; Del Mastro L;
    Oncologist; 2013; 18(8):924-5. PubMed ID: 23939283
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Acute hematologic feasibility of G-CSF supported dose-escalated FEC therapy as adjuvant treatment after breast cancer surgery.
    Ottosson S; Magnusson K; Hultborn R
    Anticancer Res; 1999; 19(5C):4429-34. PubMed ID: 10650787
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A retrospective evaluation of chemotherapy dose intensity and supportive care for early-stage breast cancer in a curative setting.
    Lyman GH; Dale DC; Tomita D; Whittaker S; Crawford J
    Breast Cancer Res Treat; 2013 Jun; 139(3):863-72. PubMed ID: 23771731
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Maintaining Dose Intensity of Adjuvant Chemotherapy in Older Patients With Breast Cancer.
    Ladwa R; Kalas T; Pathmanathan S; Woodward N; Wyld D; Sanmugarajah J
    Clin Breast Cancer; 2018 Oct; 18(5):e1181-e1187. PubMed ID: 29778788
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Febrile neutropenia in adjuvant docetaxel and cyclophosphamide (TC) with prophylactic pegfilgrastim in breast cancer patients: a retrospective analysis.
    Ngamphaiboon N; O'Connor TL; Advani PP; Levine EG; Kossoff EB
    Med Oncol; 2012 Sep; 29(3):1495-501. PubMed ID: 21818673
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.